Brief: Can-Fite Says New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy
12/09/2022 14:27
Sept 12 (Reuters) - Can-Fite Biopharma Ltd CANF.TA :
* CAN-FITE: NEW PHASE III PSORIASIS DATA SHOWING SUPERIOR
SAFETY &
IMPROVED EFFICACY PRESENTED BY KOL DR. PAPP AT THE 31ST EUROPEAN
ACADEMY OF DERMATOLOGY
Source text for Eikon: ID:nBw1ftQd0a
Further company coverage: CANF.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Can Fite Biopharma
See all newsBrief: Corrected-Can Fite Biopharma Ltd Files For Offering Of Up To 6.6 mln Ordinary Shares By Selling Shareholders
Can-Fite BioPharma rises after longer-than-anticipated overall survival in ongoing liver cancer study
Can-Fite BioPharma reports longer-than-anticipated overall survival in ongoing liver cancer study
Brief: Can Fite Biopharma Can-Fite Submits Phase 2 Study Protocol For Piclidenoson In Lowe Syndrome
Can-Fite rises as skin drug study reaches interim analysis stage